Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis

Albers, H M; Wessels, J.; Straaten, Rjh van der; Brinkman, Dmc; Suijlekom-Smit, Lisette WA van; Kamphuis, S. S. M.; Girschick, H. J.; Wouters, Carine; Schilham, MW; Cessie, Saskia le; Huizinga, T.W.J.; Cate, Rebecca ten; Guchelaar, Henk‐Jan

doi:10.1186/1546-0096-6-s1-p46

Cited by 25 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whilst a diagnosis of JIA cannot be made before 6 weeks of symptoms, all children with suspected JIA should be referred to a paediatric rheumatologist for further assessment. Referral should be made without delay in suspected JIA; a retrospective cohort study of 128 children treated with methotrexate, a commonly used agent in JIA, showed that time from diagnosis to initiation of methotrexate was an important factor in response to treatment [81]. Whilst the blood tests listed earlier are useful in diagnosing JIA and subtyping the disease, normal blood test results do not preclude a diagnosis of JIA and should not prevent referral to a paediatric rheumatologist.…”

Section: Juvenile Idiopathic Arthritismentioning

confidence: 94%

The child with joint pain in primary care

Sen

Clarke

Ramanan

2014

Best Practice & Research Clinical Rheumatology

View full text Add to dashboard Cite

Section: Juvenile Idiopathic Arthritismentioning

confidence: 94%

The child with joint pain in primary care

Sen

Clarke

Ramanan

2014

Best Practice & Research Clinical Rheumatology

View full text Add to dashboard Cite

“…The observation that the achievement of better outcomes was related with earlier treatment introduction has been reported previously for methotrexate and sulfasalazine. 5,6 In this study, the strongest association with a poor response to etanercept was the systemic-onset JIA. Systemic-onset JIA patients had 3-times higher odds to achieve a poor treatment outcome compared with the nonsystemic JIA categories and more systemic-onset JIA patients discontinued etanercept over time.…”

Section: Commentmentioning

confidence: 96%

Factors Associated With Treatment Response to Etanercept in Juvenile Idiopathic Arthritis

Otten¹,

Prince²,

Armbrust³

et al. 2011

JAMA

120

View full text Add to dashboard Cite

Among patients with JIA who initiated treatment with etanercept, one-third achieved an excellent response, one-third an intermediate response, and one-third a poor response to therapy. Achievement of an excellent response was associated with low baseline disability scores, DMARDs used before initiating etanercept, and younger age at onset of JIA. Achievement of a poor treatment response was associated with systemic JIA and female sex.

show abstract

“…Methotrexate is an effective treatment for juvenile idiopathic arthritis (JIA) and is the most commonly used disease-modifying antirheumatic drug (DMARD) for this disease [9,10]. When treatment with methotrexate is not efficacious, other immunosuppressive agents or biological drugs are usually prescribed.…”

Section: Introductionmentioning

confidence: 99%

Adherence to methotrexate in juvenile idiopathic arthritis

et al. 2011

View full text Add to dashboard Cite

Non-adherence to treatments for chronic diseases may jeopardize patients' health, increase costs of care, and cause unnecessary clinic appointments and diagnostic studies, as well as additional treatments with potentially serious side effects. Little is known about adherence to methotrexate in pediatric rheumatology. Because this medication is commonly used in JIA, we assessed adherence among children receiving methotrexate in two countries. A total of 76 outpatients (M:F 21:55) with JIA seen in Rio de Janeiro (Brazil) and in Boston (US) taking methotrexate for >2 months were enrolled. Questionnaires were completed by the parents from both centers. Non-adherence was defined as omission of ≥3 prescribed doses in the previous 8 weeks. Patients' ages ranged from 1 to 17 years. Mean time on methotrexate was 20.5 months (±25). Overall rate of non-adherence was 18%. The rate of reported non-adherence was 8% in Boston and 24% in Rio de Janeiro (P = 0.012). The main reason for non-adherence in Boston was "child refused"; in Rio de Janeiro, the main reason was inability to obtain medication. Age had a negative association with adherence (P < 0.0001). Sex, time on methotrexate, route of administration, or concomitant use of other medications were not associated with adherence. Eighteen percent of children with JIA prescribed methotrexate were non-compliant. The difference in reasons for poor adherence between patients in Rio de Janeiro and Boston suggests that different strategies may be needed to improve adherence in these 2 settings. The rate of non-adherence warrants further investigation.

show abstract

Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis

Cited by 25 publications

References 0 publications

The child with joint pain in primary care

The child with joint pain in primary care

Factors Associated With Treatment Response to Etanercept in Juvenile Idiopathic Arthritis

Adherence to methotrexate in juvenile idiopathic arthritis

Contact Info

Product

Resources

About